The prospect of molecular therapy for Angelman syndrome and other monogenic neurologic disorders

Barbara J. Bailus, David Segal

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background: Angelman syndrome is a monogenic neurologic disorder that affects 1 in 15,000 children, and is characterized by ataxia, intellectual disability, speech impairment, sleep disorders, and seizures. The disorder is caused by loss of central nervous system expression of UBE3A, a gene encoding a ubiquitin ligase. Current treatments focus on the management of symptoms, as there have not been therapies to treat the underlying molecular cause of the disease. However, this outlook is evolving with advances in molecular therapies, including artificial transcription factors a class of engineered DNA-binding proteins that have the potential to target a specific site in the genome.Results: Here we review the recent progress and prospect of targeted gene expression therapies. Three main issues that must be addressed to advance toward human clinical trials are specificity, toxicity, and delivery.Conclusions: Artificial transcription factors have the potential to address these concerns on a level that meets and in some cases exceeds current small molecule therapies. We examine the possibilities of such approaches in the context of Angelman syndrome, as a template for other single-gene, neurologic disorders.

Original languageEnglish (US)
Article number76
JournalBMC Neuroscience
Volume15
DOIs
StatePublished - Jun 19 2014

Fingerprint

Angelman Syndrome
Nervous System Diseases
Transcription Factors
DNA-Binding Proteins
Ataxia
Therapeutics
Ligases
Ubiquitin
Intellectual Disability
Genetic Therapy
Genes
Seizures
Central Nervous System
Clinical Trials
Genome
Gene Expression

Keywords

  • Angelman syndrome
  • Artificial transcription factor
  • Autism spectrum disorders
  • Blood-brain barrier
  • CRISPR
  • Engineered zinc finger
  • Gene regulation
  • Gene therapy
  • TALE

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Neuroscience(all)

Cite this

The prospect of molecular therapy for Angelman syndrome and other monogenic neurologic disorders. / Bailus, Barbara J.; Segal, David.

In: BMC Neuroscience, Vol. 15, 76, 19.06.2014.

Research output: Contribution to journalArticle

@article{badbd60dbfa44f3aad520887ab198249,
title = "The prospect of molecular therapy for Angelman syndrome and other monogenic neurologic disorders",
abstract = "Background: Angelman syndrome is a monogenic neurologic disorder that affects 1 in 15,000 children, and is characterized by ataxia, intellectual disability, speech impairment, sleep disorders, and seizures. The disorder is caused by loss of central nervous system expression of UBE3A, a gene encoding a ubiquitin ligase. Current treatments focus on the management of symptoms, as there have not been therapies to treat the underlying molecular cause of the disease. However, this outlook is evolving with advances in molecular therapies, including artificial transcription factors a class of engineered DNA-binding proteins that have the potential to target a specific site in the genome.Results: Here we review the recent progress and prospect of targeted gene expression therapies. Three main issues that must be addressed to advance toward human clinical trials are specificity, toxicity, and delivery.Conclusions: Artificial transcription factors have the potential to address these concerns on a level that meets and in some cases exceeds current small molecule therapies. We examine the possibilities of such approaches in the context of Angelman syndrome, as a template for other single-gene, neurologic disorders.",
keywords = "Angelman syndrome, Artificial transcription factor, Autism spectrum disorders, Blood-brain barrier, CRISPR, Engineered zinc finger, Gene regulation, Gene therapy, TALE",
author = "Bailus, {Barbara J.} and David Segal",
year = "2014",
month = "6",
day = "19",
doi = "10.1186/1471-2202-15-76",
language = "English (US)",
volume = "15",
journal = "BMC Neuroscience",
issn = "1471-2202",
publisher = "BioMed Central",

}

TY - JOUR

T1 - The prospect of molecular therapy for Angelman syndrome and other monogenic neurologic disorders

AU - Bailus, Barbara J.

AU - Segal, David

PY - 2014/6/19

Y1 - 2014/6/19

N2 - Background: Angelman syndrome is a monogenic neurologic disorder that affects 1 in 15,000 children, and is characterized by ataxia, intellectual disability, speech impairment, sleep disorders, and seizures. The disorder is caused by loss of central nervous system expression of UBE3A, a gene encoding a ubiquitin ligase. Current treatments focus on the management of symptoms, as there have not been therapies to treat the underlying molecular cause of the disease. However, this outlook is evolving with advances in molecular therapies, including artificial transcription factors a class of engineered DNA-binding proteins that have the potential to target a specific site in the genome.Results: Here we review the recent progress and prospect of targeted gene expression therapies. Three main issues that must be addressed to advance toward human clinical trials are specificity, toxicity, and delivery.Conclusions: Artificial transcription factors have the potential to address these concerns on a level that meets and in some cases exceeds current small molecule therapies. We examine the possibilities of such approaches in the context of Angelman syndrome, as a template for other single-gene, neurologic disorders.

AB - Background: Angelman syndrome is a monogenic neurologic disorder that affects 1 in 15,000 children, and is characterized by ataxia, intellectual disability, speech impairment, sleep disorders, and seizures. The disorder is caused by loss of central nervous system expression of UBE3A, a gene encoding a ubiquitin ligase. Current treatments focus on the management of symptoms, as there have not been therapies to treat the underlying molecular cause of the disease. However, this outlook is evolving with advances in molecular therapies, including artificial transcription factors a class of engineered DNA-binding proteins that have the potential to target a specific site in the genome.Results: Here we review the recent progress and prospect of targeted gene expression therapies. Three main issues that must be addressed to advance toward human clinical trials are specificity, toxicity, and delivery.Conclusions: Artificial transcription factors have the potential to address these concerns on a level that meets and in some cases exceeds current small molecule therapies. We examine the possibilities of such approaches in the context of Angelman syndrome, as a template for other single-gene, neurologic disorders.

KW - Angelman syndrome

KW - Artificial transcription factor

KW - Autism spectrum disorders

KW - Blood-brain barrier

KW - CRISPR

KW - Engineered zinc finger

KW - Gene regulation

KW - Gene therapy

KW - TALE

UR - http://www.scopus.com/inward/record.url?scp=84902714394&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902714394&partnerID=8YFLogxK

U2 - 10.1186/1471-2202-15-76

DO - 10.1186/1471-2202-15-76

M3 - Article

C2 - 24946931

AN - SCOPUS:84902714394

VL - 15

JO - BMC Neuroscience

JF - BMC Neuroscience

SN - 1471-2202

M1 - 76

ER -